Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • prognosFACTOR®
    • Marketplace
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey
      • Physician Segmentation
      • Outcomes
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
      • Risk Adjustment & Quality Analytics
  • Company
    • Careers
    • Events
    • News
    • Insights
  • Contact Us
Home Insights Diabetes and RA: Further Explanations for Comorbidity

Diabetes and RA: Further Explanations for Comorbidity

  • November 16, 2017
  • Posted in Lab Testing Insights

This post was last updated on December 2, 2019 at 9:41 pm

Doctor speaking with man

Why, how, and what might be next?

By Jason Bhan, MD, Fernando Schwartz, PhD, and Lauren Wiener

If you’ve been following along with us through this series, you know the team at Prognos has been investigating diabetes and rheumatoid arthritis.  Our goal has been to find evidence that diabetes and RA, which are both systemic inflammatory diseases, are also comorbid conditions, while also investigating how this is impacted by disease severity.

In our last blog, we talked you through how our analysis did find evidence of a diabetes and rheumatoid arthritis comorbidity.  Within the Prognos Registry, nearly 30% of patients suffering from RA also suffer from diabetes.  We also found that those RA patients with a double positive diagnosis were actually less likely to also suffer from diabetes.

What This Means

The results of our comorbidity analysis show a strong comorbidity between diabetes and RA, which has yet to be reported with a sample size on this scale. A striking 28.79% of RA patients were found to be diagnosed with diabetes, and 2.51% of diabetes patients were found to have RA. These significant comorbidities could be reflected in standards of care, which would enable physicians to more effectively monitor their diabetes or RA patients for progression of the other disease.

We must admit, it was somewhat surprising to find that a double positive diagnosis was more common in patients who are diagnosed with only RA as compared to comorbid patient with diabetes and RA. Furthermore, our p value was very strong and the observed difference of double positive diagnosis between the two populations is statistically significant. There are a variety of reasons why we may have observed such a difference between a population with only RA and a comorbid population.

One possibility is that this difference is associated with lifestyle choices. It is possible that patients who are more conscious of their health go to the doctor more frequently for tests and monitoring of their RA and are more likely to catch a double positive diagnosis. This health-conscious and doctor compliant population could also be less likely to have diabetes.

Another particularly exciting possibility is that our analysis has uncovered a true independent difference between comorbid and RA only patients. Perhaps diabetes provides some sort of protection against having a double positive RA diagnosis.

What’s Next

The results of our investigation certainly beg the question “what’s next?”.  While we can’t say for sure, our comorbidity results could be reflected in standards of care in the future. Physicians could monitor diabetic patients for progression of RA, which can benefit from early intervention.

If we were to further our investigation, an interesting direction for Prognos to pursue could be to only include patients that are diagnosed with RA by lab tests, and exclude patients diagnosed by only ICD codes. This approach could yield more accurate rates of a double positive diagnosis, and could ameliorate the bias over-reporting non-double positive RA patients.

Another option would be further research and consultation with endocrine and rheumatology specialists to examine the possibility of a physiological relationship between a double positive diagnosis and diabetes. A physiological link may explain why a double positive diagnosis would be less common in a comorbid population than a population of patients with only RA.

Thanks for Reading!

>We appreciate your joining us to explore the comorbidity between diabetes and RA.  As always, we encourage you to follow along with us and to reach out to us with questions or to request additional information.

Reading List

  • https://www.uptodate.com/contents/epidemiology-of-risk-factors-for-and-possible-causes-of-rheumatoid-arthritis?source=search_result&search=rheumatoid%20arthritis%20risk%20factors&selectedTitle=1~150
  • http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/dxc-20197390
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419905/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079714/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145120/
« Comorbidity Between Diabetes and RA
5 ways to optimize sales force efficiency with lab data and AI »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Omnichannel Marketing
  • Physician Segmentation
  • Prog Spotlight
  • Technology

Archives

Latest Tweets

Prognos HealthFollow

Prognos Health
prognosAIPrognos Health@prognosAI·
19 Feb

#HealthcareAnalytics are evolving.

On Tuesday February 23, Prognos Health co-founder and CEO, @sundeepbhan, will join @Safeguard for a virtual discussion on the healthcare data revolution with @GKurtzman.

Register: https://us02web.zoom.us/webinar/register/WN_WlCiq5v2TICwSMRi-PVGZw

#HealthcareData #prognosFACTOR

Reply on Twitter 1362875761674354689Retweet on Twitter 1362875761674354689Like on Twitter 1362875761674354689Twitter 1362875761674354689
prognosAIPrognos Health@prognosAI·
11 Feb

Find a way, or make a way. It’s the Prognos mantra embraced by Ali Koc, VP of Engineering at Prognos Health.

In his latest blog post, Ali writes about making data accessible at web speeds, and how it enables data analysis in a truly new way.

https://prognoshealth.com/blog/find-a-way-or-make-a-way-building-an-interactive-analytics-platform-that-speaks-healthcare/

#HealthTech

Reply on Twitter 1359933724088020994Retweet on Twitter 1359933724088020994Like on Twitter 13599337240880209942Twitter 1359933724088020994
prognosAIPrognos Health@prognosAI·
28 Jan

#TBT to our webinar featuring #LifeSciences thought leaders from @Novartis, @TakedaPharma, and @pfizer as well as Prognos Co-founder @jmbhan.

Our latest blog explores 9 insights from these experts for driving #Commercial #LaunchExcellence in #Pharma

https://prognoshealth.com/blog/overheard-at-the-reuters-health-webinar-9-insights-for-driving-commercial-launch-excellence/

Reply on Twitter 1354901342679146499Retweet on Twitter 1354901342679146499Like on Twitter 13549013426791464991Twitter 1354901342679146499
prognosAIPrognos Health@prognosAI·
22 Jan

Uncovering the (Clinical) Truth.

Bill Bowman and @olatulekan write about the intersection where #MachineLearning meets disease-specific #clinical knowledge - #ClinicalTruths - and how this improves #PatientOutcomes with #HealthcareAnalytics at scale.

https://prognoshealth.com/blog/uncovering-the-clinical-truth/

Reply on Twitter 1352709796135391237Retweet on Twitter 13527097961353912371Like on Twitter 13527097961353912373Twitter 1352709796135391237
prognosAIPrognos Health@prognosAI·
31 Dec

As we ring in the new year, there's so much to look forward to. We wish all of our clients, and partners a healthy, happy new year and are excited to continue innovating together in 2021 to positively impact care.

Reply on Twitter 1344647644669468672Retweet on Twitter 1344647644669468672Like on Twitter 13446476446694686722Twitter 1344647644669468672
Load More...
  • prognosFACTOR®
    • Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • Events
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2021. All Rights Reserved.

See What Decision Speed Looks Like in Action

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.